GLP1R and metabolic dysfunction-associated steatohepatitis: This is reflected in the substantial improvement in NASH after treatment with metabolic bariatric surgery, GLP-1R agonists (semaglutide), glucagon receptor/GLP-1R dual agonists (survodutide), or specific hepatic thyroid hormone receptor β agonists (resmetirom) [83,84,85,86].